Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 11/20 | 0.61 |
| ▸ | F13A1 | P00488 | 2/20 | 0.61 |
| ▸ | TGM1 | P22735 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | THRA | P10827 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL439369 | 0.85 | TGM2 (0.79) | TGM2F13A1TGM1LMNATGM3 | |
| SCHEMBL31693012 | 0.85 | F2 (0.65) | TGM2F13A1TGM1LMNATGM3 | |
| SCHEMBL17327878 | 0.82 | TGM2 (0.63) | TGM2F13A1TGM1LMNATGM3 | |
| SCHEMBL890715 | 0.82 | TGM2 (0.68) | TGM2F13A1TGM1LMNATGM3 | |
| SCHEMBL7470743 | 0.81 | TGM2 (0.67) | TGM2F13A1TGM1LMNATGM3 | |
| Hydroxyl Radical SCHEMBL28150321 | 0.81 | TGM2 (0.66) | TGM2F13A1TGM1LMNATGM3 | |
| SCHEMBL23609793 | 0.81 | PARP1 (0.57) | TGM2ALDH1A1MAPTKMT2A | |
| SCHEMBL6481884 | 0.80 | TGM2 (0.66) | TGM2F13A1TGM1LMNATGM3 | |
| SCHEMBL7785803 | 0.80 | TGM2 (0.66) | TGM2F13A1TGM1LMNATGM3 | |
| SCHEMBL29054310 | 0.80 | TGM2 (0.66) | TGM2F13A1TGM1LMNATGM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117986455-B | Preparation method of thickening tackifier for oil field | 东营江源化工有限公司 | 2024-05-31 | — | — | CN | disclosed |
| CN-117986455-A | Preparation method of thickening tackifier for oil field | 东营江源化工有限公司 | 2024-05-07 | — | — | CN | disclosed |
| EP-3057956-B1 | POLYCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | DANA FARBER CANCER INST INC (US) | 2021-05-05 | — | — | EP | disclosed |
| US-10906889-B2 | Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| WO-2019144149-A2 | TREATMENT METHODS FOR PANCREATIC TUMORS ASSOCIATED WITH THE WORST PROGNOSIS | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2019-07-25 | — | — | WO | disclosed |
| US-20190031642-A1 | POLYCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | PARAZA PHARMA, INC. (CA) | 2019-01-31 | — | — | US | disclosed |
| EP-1591462-A2 | Temperature-responsive polymer compound and process for producing the same | Amersham Biosciences KK (JP) | 2005-11-02 | — | — | EP | disclosed |
| US-6956077-B1 | Temperature-responsive polymer compound and process for producing the same | AMERSHAM BIOSCIENCES KK (JP) | 2005-10-18 | — | — | US | disclosed |
| US-20050224415-A1 | Temperature-responsive polymer compound and process for producing the same | AMERSHAM BIOSCIENCES KK | 2005-10-13 | — | — | US | disclosed |
| EP-1153049-A1 | TEMPERATURE-RESPONSIVE POLYMER COMPOUND AND PROCESS FOR PRODUCING THE SAME | Amersham Pharmacia Biotech K.K. (JP) | 2001-11-14 | — | — | EP | disclosed |
| WO-2000044800-A1 | TEMPERATURE-RESPONSIVE POLYMER COMPOUND AND PROCESS FOR PRODUCING THE SAME | AMERSHAM PHARMACIA BIOTECH K.K. (JP) | 2000-08-03 | — | — | WO | disclosed |
| US-5719151-A | PHTHALAZINEDIONE COMPOUND; POLYMERASE INHIBITOR | SHALL SYDNEY (GB) | 1998-02-17 | — | — | US | disclosed |
| US-4940711-A | Antihypertensive N-piperazinylalkanoylanilides | RECORDATI, S.A., CHEMICAL AND PHARMACEUTICAL COMPANY (CH) | 1990-07-10 | — | — | US | disclosed |
| EP-0120558-B1 | ANTIHYPERTENSIVE N-PIPERAZINYLALKANOYLANILIDES | RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY (CH) | 1989-03-08 | — | — | EP | disclosed |
| EP-0120558-A1 | Antihypertensive N-piperazinylalkanoylanilides | RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY (CH) | 1984-10-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10906889-B2 | Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7) | CDK13, CDK3, CDK12 | TGM2 3598/4885F13A1 1851/4885TGM1 3193/4885 |
| US-20190031642-A1 | POLYCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK13, CDK3, CDK12 | TGM2 3598/4885F13A1 1851/4885TGM1 3193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.